Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 727-732

  Marquet, Pierre ^a,b  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Allograft transplantation; Cyclosporine; MAP Bayesian estimation; Mycophenolic acid; Population pharmacokinetics

Indexed keywords

CREATININE; CYCLOSPORIN A; DACLIZUMAB; DRUG METABOLITE; ERYTHROPOIETIN; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; CYCLOSPORIN; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ANEMIA; AREA UNDER THE CURVE; BAYES THEOREM; CANCER; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG RESPONSE; DRUG SUBSTITUTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY GRAFT; METABOLIC DISORDER; NEPHROTOXICITY; PATIENT CARE; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTICLE; CONTROLLED CLINICAL TRIAL; KIDNEY TRANSPLANTATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

AREA UNDER CURVE; BAYES THEOREM; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MULTICENTER STUDIES; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 33646842570     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000179848.65266.aa     Document Type: Conference Paper

References (21)

1. Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit. 1995;17:690-699.
2. Cox VC, Ensom MHH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003;25:137-157.
3. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
4. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
5. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4:1289-1295.
6. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
7. Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet. 2001;40:375-382.
8. Leger F, Debord J, Le Meur Y, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet. 2002;41:71-80.
9. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit. 2003;25:28-35.
10. 0-12 monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol. 2003;58:813-820.
11. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit. 2004;26:23-30.
12. Saint-Marcoux F. Pharmacokinetics and therapeutic drug monitoring of cyclosporine in solid-organ transplant recipients. PhD Thesis, Limoges, France, November 9, 2004.
13. Risco E, Marquet P, Debord J, et al. Estimation of mycophenolate area under the curve by a limited sampling strategy in kidney transplant patients [Abstract]. Fundam Clin Pharmacol. 1999;13:343.
14. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000;22:169-173.
15. Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit. 2000;22:549-554.
16. Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc. 2001;33:1052-1053.
17. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504.
18. Schütz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc. 1998;30:1182-1184.
19. Le Guellec C, Büchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol. 2002;57:805-811.
20. Prémaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients orally administered mycophenolate mofetil. Clin Pharmacokinet. 2005;44(8):837-847
21. Prémaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different post-grafting periods. Ther Drug Monit. 2005;27:354-361.